3SBio (STU:83B) EBIT: €1,312 Mil (TTM As of Dec. 2025)


STU:83B 3SBio Inc STU:83B
90 GF Score
Price €1.73
GF Value €1.51
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is 3SBio EBIT?

3SBio STU:83B -3.21% 90 EBIT is €1,312 Mil as of Dec. 2025. GuruFocus rates STU:83B with a GF Score™ of 90/100 and a GF Value™ of €1.51 (Modestly Overvalued). The stock has 1 warning sign investors should review.

3SBio's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €1,109 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €1,312 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. 3SBio's annualized ROC % for the quarter that ended in Dec. 2025 was 92.29%. 3SBio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 314.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. 3SBio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 48.00%.


3SBio  (STU:83B) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

3SBio's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=2257.98 * ( 1 - 15.55% )/( (2054.368 + 2078.066)/ 2 )
=1906.86411/2066.217
=92.29 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2877.394 - 143.572 - ( 742.641 - max(0, 507.505 - 1186.959+742.641))
=2054.368

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4395.415 - 103.889 - ( 2346.776 - max(0, 535.409 - 2748.869+2346.776))
=2078.066

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

3SBio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2218.852/( ( (647.66 + max(44.659, 0)) + (671.301 + max(45.356, 0)) )/ 2 )
=2218.852/( ( 692.319 + 716.657 )/ 2 )
=2218.852/704.488
=314.96 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(170.359 + 109.011 + 53.965) - (143.572 + 0 + 145.104)
=44.659

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(122.865 + 127.04 + 106.58) - (103.889 + 0 + 207.24)
=45.356

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

3SBio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=1311.638/2732.800
=48.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


3SBio EBIT Related Terms


3SBio EBIT Historical Data

* Premium members only.

The historical data trend for 3SBio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3SBio EBIT Chart

3SBio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 268.90 322.58 281.35 381.56 1,312.49

3SBio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 116.59 195.44 181.37 202.21 1,109.43

STU:83B vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, 3SBio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 3SBio's EV-to-EBIT falls into.


STU:83B
90GF Score
3SBio Inc STU:83B
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3SBio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1,312 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €1,312 Mil mean?
3SBio (STU:83B) has a EBIT of €1,312 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on 3SBio.
Is 3SBio's EBIT too high?
3SBio's current EBIT is €1,312 Mil. Overall, 3SBio has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 3SBio's EBIT compare to VRTX and REGN?
3SBio's EBIT of €1,312 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on 3SBio. 3SBio's current EBIT is €1,312 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3SBio stock overvalued right now?
Based on GuruFocus' analysis, 3SBio (STU:83B) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.51, compared to a current price of €1.73 — trading 14.5% above its estimated fair value. The current EBIT is €1,312 Mil. 3SBio's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For 3SBio (STU:83B), the current EBIT is €1,312 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3SBio (STU:83B) Overvalued in 2026?

Based on GuruFocus' analysis, 3SBio stock appears to be overvalued. The current stock price of €1.73 is trading 14.5% above its estimated GF Value™ of €1.51. GuruFocus considers 3SBio to be Modestly Overvalued.

Key valuation signals for STU:83B:

  • EBIT: €1,312 Mil
  • GF Value™: €1.51 vs. price of €1.73 (14.5% above fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the STU:83B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


3SBio Business Description

Other Exchanges TRSBF:USA01530:Hong Kong
Address No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN
3SBio Inc is an investment holding company. It is a primary biotechnology company. The company is principally engaged in the development, production, marketing and sale of biopharmaceutical products in the People's Republic of China. The group has only one operating segment. It has presence in Chinese mainland, USA, Other countries/regions. The majority of revenue comes from USA. The core commercialized products of the group include several bio-pharmaceutical drugs, namely, TPIAO, recombinant human erythropoietin (rhEPO) products EPIAO and SEPO, Yisaipu and Cipterbin, and a small molecule drug, Mandi series of minoxidil drugs.
90GF Score

Get the complete analysis for STU:83B

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.73
Price
€1.51
GF Value